GlassScriptPhysician profile
Dolores Prudent
NPI 1760844997
$973.73
in general payments reported to CMS, 2019-2025
21 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.43 · 2020: $34.05 · 2021: $64.95 · 2022: $52.42 · 2023: $133 · 2024: $303 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $229.01 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $95.18 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $90.71 | 2023-2024 | Cologuard Collection Kit |
| Philips North America LLC | $83.42 | 2024 | (Ck4) Mcot |
| Coloplast Corp | $61.06 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $53.25 | 2023-2024 | Xarelto |
| Pfizer INC. | $43.93 | 2024-2025 | |
| Abbott Laboratories | $37.93 | 2024-2025 | Freestyle Libre |
| Astellas Pharma US INC | $36.03 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $30.51 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $28.63 | 2025 | |
| Myriad Genetic Laboratories, INC. | $25.64 | 2025 | Prolaris |
| Boston Scientific Corporation | $23.25 | 2025 | Ams 800 Artificial Urinary Sphincter |
| Clarus Therapeutics INC. | $22.21 | 2021 | |
| Dexcom, INC. | $18.02 | 2024 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $17.74 | 2021 | |
| Sumitomo Pharma America, INC. | $17.66 | 2025 | Gemtesa |
| Amgen INC. | $17.45 | 2020 | |
| Urovant Sciences INC | $15.41 | 2022 | |
| Glaxosmithkline, LLC. | $14.10 | 2024 | Arexvy |
| Laborie Medical Technologies Corp. | $12.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dolores Prudent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.